Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
India · Delayed Price · Currency is INR 216.90
+0.65 (0.30%)
Nov 12, 2026, 3:30 PM IST
Jagsonpal Pharmaceuticals Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 14,328 | 12,323 | 14,422 | 7,313 | 7,592 | 8,214 | |
Market Cap Growth | 0.86% | -14.55% | 97.22% | -3.68% | -7.58% | 293.91% |
Enterprise Value | 13,304 | 10,819 | 13,741 | 6,290 | 7,175 | 7,748 |
Last Close Price | 216.73 | 181.00 | 211.47 | 106.43 | 110.29 | 119.33 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 32.54 | 28.60 | 26.05 | 32.55 | 28.41 | 43.57 |
PS Ratio | 4.54 | 4.29 | 5.37 | 3.50 | 3.21 | 3.78 |
PB Ratio | 5.87 | 4.46 | 6.01 | 3.90 | 4.78 | 6.19 |
P/TBV Ratio | 10.02 | 6.22 | 9.35 | 3.90 | 4.78 | 6.19 |
P/FCF Ratio | 30.18 | 26.41 | 26.33 | 20.94 | 16.39 | 140.06 |
P/OCF Ratio | 30.10 | 26.33 | 26.17 | 20.80 | 16.27 | 118.81 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 4.21 | 3.77 | 5.11 | 3.01 | 3.03 | 3.56 |
EV/EBITDA Ratio | 21.61 | 19.16 | 27.69 | 28.44 | 20.67 | 30.37 |
EV/EBIT Ratio | 25.33 | 22.25 | 32.00 | 29.11 | 21.18 | 32.30 |
EV/FCF Ratio | 28.02 | 23.19 | 25.09 | 18.01 | 15.49 | 132.10 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.04 | 0.03 | 0.04 | 0.05 | 0.04 | - |
Debt / EBITDA Ratio | 0.15 | 0.14 | 0.18 | 0.38 | 0.17 | - |
Debt / FCF Ratio | 0.19 | 0.18 | 0.17 | 0.26 | 0.13 | - |
Net Debt / Equity Ratio | -0.43 | -0.35 | -0.50 | -0.74 | -0.68 | -0.35 |
Net Debt / EBITDA Ratio | -1.77 | -1.73 | -2.40 | -6.29 | -3.13 | -1.84 |
Net Debt / FCF Ratio | -2.23 | -2.09 | -2.18 | -3.98 | -2.34 | -8.02 |
Asset Turnover | 1.02 | 0.97 | 1.09 | 1.01 | 1.32 | 1.33 |
Inventory Turnover | 5.70 | 7.08 | 6.45 | 4.52 | 3.68 | 3.02 |
Quick Ratio | 2.82 | 4.35 | 5.47 | 8.31 | 4.92 | 2.32 |
Current Ratio | 3.42 | 5.06 | 6.22 | 10.29 | 5.97 | 4.04 |
Return on Equity (ROE) | 18.18% | 16.70% | 25.91% | 12.97% | 18.32% | 14.81% |
Return on Assets (ROA) | 10.63% | 10.22% | 10.84% | 6.55% | 11.79% | 9.13% |
Return on Invested Capital (ROIC) | 24.84% | 24.35% | 40.26% | 32.94% | 38.26% | 22.30% |
Return on Capital Employed (ROCE) | 19.90% | 16.90% | 17.00% | 10.90% | 20.20% | 17.50% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 11, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 3.07% | 3.50% | 3.84% | 3.07% | 3.52% | 2.30% |
FCF Yield | 3.31% | 3.79% | 3.80% | 4.78% | 6.10% | 0.71% |
Dividend Yield | 1.15% | 1.36% | 1.15% | 1.81% | 1.73% | 1.28% |
Payout Ratio | 58.38% | 38.67% | 23.90% | 58.31% | - | 55.58% |
Buyback Yield / Dilution | -0.46% | -1.33% | -1.56% | -1.23% | - | - |
Total Shareholder Return | 0.70% | 0.02% | -0.40% | 0.58% | 1.73% | 1.28% |